Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 27 (1984), S. 153-157 
    ISSN: 1432-1041
    Keywords: verapamil ; hydrochlorothiazide ; serum lipids ; blood glucose ; serum insulin ; serum and urine electrolytes ; calcium hypertension
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The effect of verapamil on different metabolic parameters has been studied after changing the treatment of hypertension from hydrochlorothiazide to verapamil monotherapy. Verapamil 80 to 160 mg b.i.d. was continued for 6 months. The antihypertensive efficacy of verapamil was comparable to that of hydrochlorothiazide. Plasma total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and free fatty acids did not change significantly after the change in treatment; serum total cholesterol, LDL-cholesterol and HDL-cholesterol were 7.28±1.80 (m±SD), 5.11±1.59 and 1.65±0.39 mmol/l at the end of the hydrochlorothiazide period and 7.10±1.92, 5.09±1.70 and 1.56±0.35 mmol/l at the end of the verapamil period, respectively. The only statistically significant differences were the increases in total and LDL-cholesterol after three months on verapamil as compared to the basal values before diuretic therapy. Marked changes were not observed in fasting blood glucose, insulin or C-peptide values. Serum uric acid concentration decreased significantly (p〈0.001) from 326±66 to 252±53 mmol/l, and serum potassium level increased significantly (p〈0.01) from 3.5±0.4 to 3.9±0.3 mmol/l, on verapamil as compared to the diuretic period. Serum calcium decreased from 2.45±0.10 to 2.37±0.08 mmol/l (p〈0.01) and calcium excretion increased significantly (p〈0.01) to 5.43±2.55 mmol/24 h during verapamil administration from the level of 3.56±2.78 mmol/24 h whilst on the diuretic.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 43 (1992), S. 365-368 
    ISSN: 1432-1041
    Keywords: Doxazosin ; Hypertension ; Diabetes mellitus ; non-insulin dependent diabetes mellitus ; insulin sensitivity ; serum lipids ; adverse drug effects
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The effect of doxazosin, an a,-adrenoceptor blocking drug, on blood pressure, sensitivity to insulin and serum lipids has been evaluated in 14 hypertensive, non-insulin dependent diabetic patients. The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved. After 12 weeks of treatment (mean doxazosin dose 5.6 ± 5.1 mg daily), the supine and standing diastolic blood pressure of the patients had declined by about 7 mmHg, whereas their systolic blood pressure and heart rate were not significantly changed. The metabolic clearance rate of glucose increased from 2.35 to 3.37 ml - min−1 - kg−1 during treatment, suggesting improved sensitivity to insulin. Fasting plasma glucose was 11.9 mmol·1−1 before and 10.9 mmol·l−1 after doxazosin therapy (NS). Serum electrolytes and lipids did not change significantly but serum uric acid decreased from 305 to 281 μmol · 1−1 Doxazosin may be a useful alternative for the treatment of hypertension in NIDDM patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...